PARADISE MI

The goal of the trial was to assess the efficacy and safety of sacubitril/valsartan compared with ramipril in a contemporary acute myocardial infarction (AMI) IN THIS, 5,660 PATIENTS FROM 43 COUNTRIES WITH MEAN AGE OF 64 YEARS WITH PRIOR MI WITH Left ventricular ejection fraction ≤40% with or without pulmonary congestion WERE RANDOMIZED TO RECEIVE EITHER sacubitril/valsartan OR RAMIPRIL AND WERE FOLLOWED UP FOR 23 MONTHS. THE RESULT OF THE TRIAL SHOWED THAT, The primary outcomes of CV death or HF hospitalization were not statistically different between the groups. In the secondary outcomes, the composite endpoint of all Heart Failure events & mortality showed a significance of 0.02 No major adverse events were seen either in both arms. Interestingly, although the events were numerically lower, the trial did not reach its statistical target to show the clinical benefit of sacubitril/valsartan over standard Ramipril in post-MI patients. Disclaimer: Lupin makes no representation or warranty of any kind, expressed or implied, regarding the accuracy, adequacy, validity, reliability, availability or completeness of any scientific information shared by the HCP on the ­­­STAR UPDATE podcast. You should not allow the contents of this to substitute for your own medical judgment, which you should exercise in evaluating the information on this website.